PSOARING 3 was an open-label, long-term extension study designed to evaluate safety, durability of response, and duration of remittive effect (median time to first worsening) of VTAMA cream over 40 weeks.3
73 patients who achieved complete disease clearance (PGA=0) after 12 weeks of VTAMA cream treatment entered the open-label, long-term extension (LTE) study and stopped treatment.1
Patients off-treatment maintained a PGA score of 0 or 1 for a median of 114 days (95% CI: 85 to 142 days) without disease worsening (defined as PGA≥2 [mild])1,3
Join us and other dedicated healthcare professionals in revolutionizing the way we see plaque psoriasis. Sign up below for updates and other helpful information.